1.
Bioorg Med Chem Lett
; 27(18): 4500-4505, 2017 09 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28802631
RESUMO
Leucine-rich repeat kinase 2 (LRRK2) has attracted considerable interest as a therapeutic target for the treatment of Parkinson's disease. Compounds derived from a 2-aminopyridine screening hit were optimised using a LRRK2 homology model based on mixed lineage kinase 1 (MLK1), such that a 2-aminopyridine-based lead molecule 45, with in vivo activity, was identified.